Выбор редакции

Repros Therapeutics' (RPRX) Proellex Positive in Phase II

Repros Therapeutics Inc. RPRX announced positive results from a phase II study, evaluating its pipeline candidate, Proellex, for the treatment of premenopausal women with moderate to severe endometriosis.

The double-blinded phase II study showed encouraging outcomes with 70% of the patients treated with oral Proellex experiencing relief from menstrual pain and a reduction in the use of pain medication compared to the placebo arm. Menstrual pain, as measured by the BBSS (Biberoglu and Behrman Symptom Score) score, in patients treated with Proellex decreased significantly, compared to those treated with placebo. Pill count of subjects treated with Proellex showed a reduction of 56% compared 30% in the placebo arm. Proellex was found to be well tolerated in the study.

The drug was tested on 60 subjects with a mean age group of 30, comprising 13 patients from Argentina and 47 from the U.S.

Currently, there are no FDA-approved oral drugs for the long-term treatment of uterine fibroids or endometriosis.

If successfully developed and commercialized, Proellex could prove to be a breakthrough treatment, catering to a huge population of women. According to the Endometriosis Association, the disease is estimated to affect 6.3 million women in the U.S. and Canada, and millions more in the rest of the world.

Repros is planning to have a discussion with the FDA for the late-stage development of Proellex and phase III studies to treat women struggling with painful menstruation.

Zacks Rank & Other Key Picks

Repros Therapeutics currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the medical genetics sector include ANI Pharmaceuticals, Inc. ANIP, Anika Therapeutics Inc. ANIK and Cambrex Corporation CBM. Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
REPROS THERAPEU (RPRX): Free Stock Analysis Report
 
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
 
CAMBREX CORP (CBM): Free Stock Analysis Report
 
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research